Oral pharmacotherapeutics for the management of peripheral neuropathic pain conditions – a review of clinical trials

References

• International Association for the Study of Pain, Washington,cited 2020 Jul 11. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Neuropathicpain
   Google Scholar
• Bannister K, Sachau J, Baron R, et al. Neuropathic pain: mechanism-based therapeutics. Annu Rev Pharmacol Toxicol. 2020 Jan;6(60):257–274.
   Web of Science ®Google Scholar
• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654–662.
   PubMed Web of Science ®Google Scholar
• Ruiz-Negron N, Menon J, King JB, et al. Cost-effectiveness of treatment options for neuropathic pain: a systematic review. Pharmacoeconomics. 2019 May;37(5):669–688.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Bongaerts BWC, Heier M, et al. Neuropathic pain is not adequately treated in the older general population: results from the KORA F4 survey. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):806–814.
   PubMed Web of Science ®Google Scholar
• Kukkar A, Bali A, Singh N, et al. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013 Mar;36(3):237–251.
   PubMed Web of Science ®Google Scholar
• Chandra K, Shafiq N, Pandhi P, et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial–the GONIP Trial. Int J Clin Pharmacol Ther. 2006 Aug;44(8):358–363.
   PubMed Web of Science ®Google Scholar
• Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001 Dec;3(2):53–62.
   PubMedGoogle Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1831–1836.
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Postherpetic neuralgia study G. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001 Nov;94(2):215–224.
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1837–1842.
   PubMed Web of Science ®Google Scholar
• Freeman R, Wallace MS, Sweeney M, et al. Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Med.. 2015 Oct;16(10):2000–2011.
   PubMed Web of Science ®Google Scholar
• Sang CN, Sathyanarayana R, Sweeney M, et al. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013 Apr;29(4):281–288.
   PubMed Web of Science ®Google Scholar
• Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig. 2010;30(11):765–776.
   PubMed Web of Science ®Google Scholar
• Mehta N, Bucior I, Bujanover S, et al. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes.. 2016 Apr 1;14(1):54.
   PubMed Web of Science ®Google Scholar
• Sandercock D, Cramer M, Biton V, et al. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract. 2012 Sep;97(3):438–445.
   PubMed Web of Science ®Google Scholar
• Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009 Mar-Apr;25(3):185–192.
   PubMed Web of Science ®Google Scholar
• Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med.. 2011 Jul;12(7):1098–1108.
   PubMed Web of Science ®Google Scholar
• Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013 Jun;14(6):590–603.
   PubMed Web of Science ®Google Scholar
• Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013 Jul;13(6):485–496.
   PubMed Web of Science ®Google Scholar
• Harden RN, Freeman R, Rainka M, et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Med. 2013 Dec;14(12):1918–1932.
   PubMed Web of Science ®Google Scholar
• Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):251–252.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 Feb;73(2):137–150.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010 Oct;49(10):661–669.
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul;31(7):1448–1454.
   PubMed Web of Science ®Google Scholar
• Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009 Feb;9:6.
   PubMed Web of Science ®Google Scholar
• Hurley RW, Lesley MR, Adams MC, et al. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008 Sep-Oct;33(5):389–394.
   PubMed Web of Science ®Google Scholar
• Perez C, Navarro A, Saldana MT, et al. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther. 2010 Jul;32(7):1357–1370.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011 Apr;52(4):826–836.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Covvey JR, Peckham AM, et al. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the food and drug administration adverse events reporting system (FAERS). Res Social Adm Pharm. 2019 Aug;15(8):953–958.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017 Mar;77(4):403–426.
   PubMed Web of Science ®Google Scholar
• Ghaly RF, Plesca A, Rana S, et al. Gabapentin-related suicide: myth or fact? Surg Neurol Int. 2018;9(1):210.
   PubMedGoogle Scholar
• Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014 Jun;28(6):491–496.
   PubMed Web of Science ®Google Scholar
• Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019 Sep;10(5):1299–1306.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019 May;160(5):1175–1185.
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015 Feb;110:189–205.
   PubMed Web of Science ®Google Scholar
• Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 Feb;15(2):CD009318.
   Google Scholar
• de Greef BTA, Hoeijmakers JGJ, Geerts M, et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain. 2019 Feb 1;142(2):263–275.
   PubMed Web of Science ®Google Scholar
• Carmland ME, Kreutzfeldt M, Holbech JV, et al. Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial. Trials. 2019 Oct 11;20(1):588.
   PubMed Web of Science ®Google Scholar
• Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015 Apr;20(2):107–114.
   PubMed Web of Science ®Google Scholar
• Simpson DM, McArthur JC. Neuropathic pain: mechanisms, diagnosis and pain. Oxford: Oxford University Press; 2012. English.
   Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014 Apr;10(4):CD005451.
   Google Scholar
• Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017 Dec; 12(12):CD007963.
   PubMed Web of Science ®Google Scholar
• Razazian N, Baziyar M, Moradian N, et al. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014 Jul;19(3):192–198.
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhou HY, Xiao ZL, et al. Efficacy and Safety of gabapentin vs. carbamazepine in the treatment of trigeminal neuralgia: a meta-analysis. Pain Pract. 2016 Nov;16(8):1083–1091.
   PubMed Web of Science ®Google Scholar
• Kremer M, Yalcin I, Goumon Y, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. J Neurosci. 2018 Nov 14;38(46):9934–9954.
   PubMed Web of Science ®Google Scholar
• Wolff M, Czorlich P, Nagaraj C, et al. Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: an in vitro study. Neurosci Res. 2016 Aug;109:16–27.
   PubMed Web of Science ®Google Scholar
• Stepanenko YD, Boikov SI, Sibarov DA, et al. Dual action of amitriptyline on NMDA receptors: enhancement of Ca-dependent desensitization and trapping channel block. Sci Rep. 2019 Dec 19;9(1):19454.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Jul;6(7):CD008242.
   Google Scholar
• Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012 Dec;35(12):2451–2458.
   PubMed Web of Science ®Google Scholar
• Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med. 2007 Apr;24(4):377–383.
   PubMed Web of Science ®Google Scholar
• Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992 May 7;326(19):1250–1256.
   PubMed Web of Science ®Google Scholar
• Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988 Sep;38(9):1427–1432.
   PubMed Web of Science ®Google Scholar
• Hogans BB, Barreveld AM. Pain care essentials. 2020. English. New York (NY): Oxford University Press.
   Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.
   PubMed Web of Science ®Google Scholar
• Duehmke RM, Derry S, Wiffen PJ, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 15;6:CD003726.
   PubMedGoogle Scholar
• Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1–2):323–331.
   PubMed Web of Science ®Google Scholar
• Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842–1846.
   PubMed Web of Science ®Google Scholar
• Hassamal S, Miotto K, Dale W, et al. Tramadol: understanding the risk of serotonin syndrome and seizures. Am J Med. 2018 Nov;131(11):1382 e1–1382 e6.
   Web of Science ®Google Scholar
• Knezevic NN, Tverdohleb T, Knezevic I, et al. Unique pharmacology of tapentadol for treating acute and chronic pain. Expert Opin Drug Metab Toxicol. 2015;11(9):1475–1492.
   PubMed Web of Science ®Google Scholar
• Tominaga Y, Koga H, Uchida N, et al. Methodological issues in conducting pilot trials in chronic pain as randomized, double-blind, placebo-controlled studies. Drug Res (Stuttg). 2016 Jul;66(7):363–370.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011 Jan;27(1):151–162.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014 Aug;37(8):2302–2309.
   PubMed Web of Science ®Google Scholar
• Mannino R, Coyne P, Swainey C, et al. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag. 2006 Sep-Oct;2(5):269–276.
   PubMedGoogle Scholar
• McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017 May 17;5:CD012499.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul;116(1–2):109–118.
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005 Sep-Oct;6(5):346–356.
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006 Oct 24;67(8):1411–1420.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Arslanian A, Nothaft W, et al. Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain. 2012 Apr;153(4):862–868.
   PubMed Web of Science ®Google Scholar
• Gao Y, Ning G, Jia WP, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010 Nov;123(22):3184–3192.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo X, Han P, et al. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs placebo. Int J Clin Pract. 2015 Sep;69(9):957–966.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Investig. 2011 Apr 7;2(2):132–139.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359–1367.
   PubMed Web of Science ®Google Scholar
• Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf. 2010 May 1;33(5):393–407.
   PubMed Web of Science ®Google Scholar
• Enomoto H, Yasuda H, Nishiyori A, et al. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin. J Pain Res. 2018;11:1857–1868.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013 Dec;154(12):2616–2625.
   PubMed Web of Science ®Google Scholar
• Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011 Jul;86(7):615–626.
   PubMed Web of Science ®Google Scholar
• Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011 Apr;34(4):818–822.
   PubMed Web of Science ®Google Scholar
• Moore RA, Chi CC, Wiffen PJ, et al. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev. 2015 Oct ;5(10):CD010902.
   Google Scholar
• Shackelford S, Rauck R, Quessy S, et al. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia. J Pain. 2009 Jun;10(6):654–660.
   PubMed Web of Science ®Google Scholar
• Wong SSC, Chan WS, Cheung CW. Analgesic Effects of cannabinoids for chronic non-cancer pain: a systematic review and meta-analysis with meta-regression. J Neuroimmune Pharmacol. 2020 Mar 14. DOI: 10.1007/s11481-020-09905-y.
   PubMed Web of Science ®Google Scholar
• Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012 Oct;153(10):2073–2082.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162–173.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015 Apr;156(Suppl 1):S104–14.
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113–e88.
   PubMed Web of Science ®Google Scholar
• Forstenpointner J, Rice ASC, Finnerup NB, et al. Up-date on clinical management of postherpetic neuralgia and mechanism-based treatment: new options in therapy. J Infect Dis. 2018 Sep 22;218(suppl_2):S120–S126.
   PubMed Web of Science ®Google Scholar
• Wang SL, Wang H, Nie HY, et al. The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: a meta-analysis. Medicine (Baltimore). 2017 Dec;96(51):e9167.
   PubMed Web of Science ®Google Scholar
• Zhang M, Gao CX, Ma KT, et al. A meta-analysis of therapeutic efficacy and safety of gabapentin in the treatment of postherpetic neuralgia from randomized controlled trials. Biomed Res Int. 2018;2018:7474207.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American diabetes association. Diabetes Care. 2017 Jan;40(1):136–154.
   PubMed Web of Science ®Google Scholar
• Parsons B, Li C. The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. Curr Med Res Opin. 2016 May;32(5):929–937.
   PubMed Web of Science ®Google Scholar
• Hossain SM, Hussain SM, Ekram AR. Duloxetine in painful diabetic neuropathy: a systematic review. Clin J Pain. 2016 Nov;32(11):1005–1010.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 9;6:CD007938.
   PubMedGoogle Scholar
• Bendtsen L, Zakrzewska JM, Abbott J, et al. European academy of neurology guideline on trigeminal neuralgia. European Journal of Neurology. 2019 Jun;26(6):831–849.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Bergeria CL, Huhn AS, et al. A systematic review of laboratory evidence for the abuse potential of tramadol in humans. Front Psychiatry. 2019;10:704.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Severtson SG, Dart RC, et al. Assessment of tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance system. J Pain. 2018 Apr;19(4):439–453.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Beaumont J, Dailey-Govoni ST, et al. Evaluation of abuse and route of administration of extended-release tapentadol among treatment-seeking individuals, as captured by the addiction severity index-multimedia version (ASI-MV). Pain Med. 2019 Oct 16;DOI:10.1093/pm/pnz250
   PubMed Web of Science ®Google Scholar
• Pachman DR, Barton DL, Watson JC, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011 Sep;90(3):377–387.
   PubMed Web of Science ®Google Scholar
• Coffeen U, Sotomayor-Sobrino MA, Jimenez-Gonzalez A, et al. Chemotherapy-induced neuropathic pain characteristics in Mexico’s national cancer center pain clinic. J Pain Res. 2019;12:1331–1339.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019 Feb 8;19(1):132.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20;32(18):1941–1967.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Ye C, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017 Mar;26(2):e12421.
   Web of Science ®Google Scholar
• Hou S, Huh B, Kim HK, et al. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician. 2018 Nov;21(6):571–592.
   PubMed Web of Science ®Google Scholar
• Hu S, Huang KM, Adams EJ, et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2019 Nov 1;25(21):6295–6301.
   PubMed Web of Science ®Google Scholar
• Wright ME, Rizzolo D. An update on the pharmacologic management and treatment of neuropathic pain. JAAPA. 2017 Mar;30(3):13–17.
   PubMedGoogle Scholar
• Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015 Dec;156(12):2616–2626.
   PubMed Web of Science ®Google Scholar
• Vachon-Presseau E, Berger SE, Abdullah TB, et al. Brain and psychological determinants of placebo pill response in chronic pain patients. Nat Commun. 2018 Sep 12;9(1):3397.
   PubMed Web of Science ®Google Scholar
• Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2006 Jan;7(1 Suppl 1):S3–S12.
   PubMed Web of Science ®Google Scholar
• Kocsis JD, Waxman SG. Ionic channel organization of normal and regenerating mammalian axons. Prog Brain Res. 1987;71:89–101.
   PubMed Web of Science ®Google Scholar
• Tsantoulas C, McMahon SB. Opening paths to novel analgesics: the role of potassium channels in chronic pain. Trends Neurosci. 2014 Mar;37(3):146–158.
   PubMed Web of Science ®Google Scholar
• Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009 Apr 1;29(13):4076–4088.
   PubMed Web of Science ®Google Scholar
• Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017 Feb 16;3(1):17002.
   PubMed Web of Science ®Google Scholar
• Yarnitsky D, Granot M, Nahman-Averbuch H, et al. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012 Jun;153(6):1193–1198.
   PubMed Web of Science ®Google Scholar
• Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009 Sep;10(9):895–926.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Gilron I, Doshi T, et al. Designing and conducting proof-of-concept chronic pain analgesic clinical trials. Pain Rep. 2019 May-Jun;4(3):e697.
   PubMedGoogle Scholar
• Raja SN, Sivanesan E, Guan Y. Central sensitization, N-methyl-D-aspartate receptors, and human experimental pain models: bridging the gap between target discovery and drug development. Anesthesiology. 2019 Aug;131(2):233–235.
   PubMed Web of Science ®Google Scholar
• Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017 Feb;158(2):261–272.
   PubMed Web of Science ®Google Scholar
• Reimer M, Helfert SM, Baron R. Phenotyping neuropathic pain patients: implications for individual therapy and clinical trials. Curr Opin Support Palliat Care. 2014 Jun;8(2):124–129.
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Wilhelm S, Schacht A, et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain. 2014 Oct;155(10):2171–2179.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014 Nov;155(11):2263–2273.
   PubMed Web of Science ®Google Scholar
• Vollert J, Magerl W, Baron R, et al. Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models. Pain. 2018 Jun;159(6):1090–1102.
   PubMed Web of Science ®Google Scholar